ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1168

Platelet Transcriptome Analysis in CKD Provides Insight into Cardiovascular Events

Session Information

  • CKD: Mechanisms - 3
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Israni, Avantika, New York University, New York, New York, United States
  • Muller, Matthew, New York University, New York, New York, United States
  • Charytan, David M., New York University, New York, New York, United States
  • Berger, Jeffrey S., New York University, New York, New York, United States
Background

Platelet dysfunction is common in patients with CKD and contributes to hemorrhagic tendencies as well as CVD, but to our knowledge effects of CKD on the platelet transcriptome have not been analyzed.

Methods

We compared the platelet transcriptome from prospectively recruited patients with peripheral artery disease according to eGFR and CKD class: moderate CKD (eGFR of 30-<60 mL/min/1.73m2), severe CKD (eGFR of < 30 mL/min/1.73,2), or chronic dialysis. Results were adjusted for age, sex, ethnicity and race.

Results

54 participants had CKD (28% male, mean age 72, and 12% Black) and 81 had preserved kidney function (62% male, mean age 69, and 15% Black). After adjusting for age, sex, race, ethnicity, and multiple comparisons, we identified 17 differentially expressed genes in moderate CKD (13 upregulated, 4 downregulated), & 344 in severe CKD (188 upregulated, 156 downregulated), and 560 in chronic dialysis (274 upregulated , 286 downregulated) compared with preserved kidney function. We defined a transcriptomic signature of 13 genes differentially expressed in CKD, and showed that this signature associated with CKD severity in a test cohort (N=40). This signature was correlated with epinephrine and ADP induced platelet aggregation and was significantly associated with mortality and major adverse cardiovascular events in adjusted analyses. In additional analyses multiple genes were significantly correlated with eGFR. Mitochondrial function and RNA function processes were particularly impacted (Figure)

Conclusion

These findings demonstrate a unique platelet transcriptomic signature in CKD that is associated with future risk of cardiovascular events.